Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143851 | 0.96 | TLR7 (0.57) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5747274 | 0.85 | TLR7 (0.51) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5749045 | 0.85 | TLR7 (0.55) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL3866002 | 0.84 | TLR7 (0.53) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL3863900 | 0.84 | TLR7 (0.53) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5748391 | 0.84 | TLR7 (0.53) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5747394 | 0.83 | TLR7 (0.56) | TLR7LMNAPOLBHRH2ADRA1D | |
| Hydrochloric Acid SCHEMBL3863251 | 0.83 | TLR7 (0.52) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL5748394 | 0.83 | TLR7 (0.53) | TLR7LMNAPOLBHRH2ADRA1D | |
| SCHEMBL3862412 | 0.83 | TLR7 (0.53) | TLR7LMNAPOLBHRH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | claimed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | claimed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | claimed |
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765071-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-9328110-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328110-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328110-B2 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| EP-1687307-B1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| EP-1687307-A4 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20070072893-A1 | Substituted imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-29 | — | — | US | disclosed |
| EP-1687307-A2 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M Innovative Properties Company (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051317-A2 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072893-A1 | Substituted imidazo ring systems and methods | IL2, IRF3, EIF2AK2 | TLR7 162/4885LMNA 3973/4885POLB 2587/4885 |
| US-20160194322-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | TLR7 155/4885LMNA 4021/4885POLB 1872/4885 |
| US-20140194628-A1 | SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS | IL2, IRF3, EIF2AK2 | TLR7 155/4885LMNA 4021/4885POLB 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.